Al's Comment:

 The Musella Foundation gave a $30,000 grant to help jumpstart the development of this drug - OKN-007 - back in 2013.  This is your donation dollars hard at work!

  They have been running a clinical trial of the drug for newly diagnosed as well as recurrent Glioblastomas.  Early reports look interesting  for recurrent glioblastoma, the median progression free survival was only 1.4 months but overall survival was 21 months.  There was no control group but historically, patients with recurrent glioblastoma rarely live over a year. 21 months would be outstanding.

They will soon be starting more clinical trials, for diffuse midline glioma, DIPG, high grade gliomas and others.  They just announced that they will soon open an expanded access program, even before these new trials start. May be worth considering.

Posted on: 09/30/2021

Oblato Announces that it has received a Positive Response from the FDA for the use of OKN-007 for patients with high-grade gliomas in an Expanded Access Program


Click HERE to return to brain tumor news headlines.

Our privacy / cookie policy has changed.
HERE to read it!